drugset / Trial / NCT00676663

Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer

NCT00676663

Phase 2 Completed 130 enrolled Syndax Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of entinostat in combination with exemestane in the treatment of advanced breast cancer.

Timeline

Start
2008-06-13
Primary completion
2011-01-29
Completion
2012-11-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Entinostat Small molecule 5 mg Oral
Background Exemestane Small molecule 25 mg Oral